WuXi Biologics to Acquire Drug Substance Facility in Wuppertal, Germany from Bayer
WuXi Biologics a global company with leading open-access biologics technology platforms, and Bayer, announced an acquisition deal, under which WuXi Biologics will take over and operate the Drug Substance (DS) facility at Bayer’s Wuppertal site. The companies also plan to enter into a long-term sublease agreement and a transition service contract. The volume of the transaction, including the sublease agreement, amounts to approximately 150 million euros.